SCHEMBL1607080

SCHEMBL1607080

COc1ccc(-c2noc(-c3ccc4[nH]nnc4c3)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 12/20 0.56
NPC1 O15118 11/20 0.56
MAPT P10636 11/20 0.56
SMN1; SMN2 Q16637 7/20 0.56
NPSR1 Q6W5P4 2/20 0.56
S1PR1 P21453 1/20 0.56
NR1H4 Q96RI1 1/20 0.56
HPGD P15428 3/20 0.54
KDM4E B2RXH2 2/20 0.54
ALDH1A1 P00352 2/20 0.54
LMNA P02545 2/20 0.53
HSD17B10 Q99714 1/20 0.53
POLB P06746 1/20 0.51
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
TP53 P04637 3/20 0.50
NFKB1 P19838 3/20 0.50
NFKB2 Q00653 3/20 0.50
RELA Q04206 3/20 0.50
TDP1 Q9NUW8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23523835 0.84 SMN1; SMN2 (0.56) RAB9ANPC1MAPTSMN1; SMN2S1PR1
SCHEMBL1250702 0.83 NPC1 (0.41) RAB9ANPC1MAPTSMN1; SMN2NPSR1
SCHEMBL24024580 0.81 PRKAG1 (0.47) RAB9ANPC1MAPTSMN1; SMN2KDM4E
SCHEMBL1251094 0.80 RAB9A (0.59) RAB9ANPC1MAPTSMN1; SMN2NPSR1
SCHEMBL1608484 0.80 MAPT (0.56) RAB9ANPC1MAPTSMN1; SMN2NPSR1
SCHEMBL12895918 0.78 RAB9A (0.76) RAB9ANPC1MAPTSMN1; SMN2NPSR1
SCHEMBL1250936 0.77 S1PR1 (0.62) RAB9ANPC1MAPTSMN1; SMN2NPSR1
SCHEMBL1423111 0.77 NPC1 (0.60) RAB9ANPC1MAPTSMN1; SMN2NPSR1
SCHEMBL1607562 0.76 NR1H4 (0.54) RAB9ANPC1MAPTSMN1; SMN2NPSR1
SCHEMBL13567154 0.75 RAB9A (0.50) RAB9ANPC1MAPTSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US claimed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US disclosed
WO-2009146343-A1 NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES MERCK & CO., INC. (US) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles APP, PSEN1, BACE1 RAB9A 4026/4885NPC1 129/4885MAPT 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.